

7 (II) BRU124EX (SEQ ID NO: 2)

8

9

10 W-X-Leu-Gln-Lys-Gln-Ile-Thr-Lys-Ile-Gln-Asn-
11 Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-
12 Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-Lys-
13 Gly-Glu-Gly-Ala-Y-Z

14 (III) BRU124F1X (SEQ ID NO: 3)

15

16

17

18

19

20

21

W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Arg-
Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-
Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Val-
Ile-Gln-Asp-Asn-Ser-Asp-Ile-Lys-Y-Z

(IV) BRU124F3X (SEQ ID NO: 4)

22

23

24

25

26

W-X-Lys-Ile-Gln-Asp-Phe-Arg-Val-Tyr-Arg-
Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-
Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Val-Val-
Ile-Gln-Asp-Asn-Y-Z

(V) ROD 124E1 (SEQ ID NO: 5)

27

28

29

30

31

32

33

W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-
Y-Z

(VI) ROD 124EX (SEQ ID NO: 6)

35

36

37

38

39

W-X-Leu-Gln-Ala-Lys-Asn-Ser-Lys-Leu-Lys-
Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-
Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-
Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

40

(VII) ROD 124C2X (SEQ ID NO: 7)

41

42

W-X-Lys-Leu-Lys-Asp-Phe-Arg-

43 Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-
44 Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
45 Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
46 Thr-Asp-Ile-Lys-Y-Z
47

48 (VIII) ROD 124C1X (SEQ ID NO: 8)

49 W-X-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-
50 Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
51 Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
52 Thr-Asp-Ile-Lys-Y-Z
53

54 (IX) ROD 123C3X (SEQ ID NO: 9)

55 X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
56 Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
57 Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-
58 Ala-Val-Leu-Val-Lys-Val-Gly-Thr-Asp-Ile-Lys-Y-
59 Z
60

61 (X) POL2A1 (SEQ ID NO: 10)

62 W-X-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
63 Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
64 Thr-Asp-Ile-Lys-Ile-Ile-Pro-Arg-Arg-Lys-
65 Ala-Lys-Ile-Ile-Y-Z
66

67 (XI) ROD124C5X (SEQ ID NO: 11)

68 W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
69 Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
70 Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-
71 Ala-Val-Leu-Val-Lys-Val-Gly-Y-Z
72
73
74

75 wherein W is either a H of the amino terminal NH₂ group of the
76 polypeptide or an additional amino acid bonded to the amino terminal NH₂ group of the
77 polypeptide, the additional amino acid being selected to facilitate coupling of the

78 polypeptide to a carrier protein or to a support; X is absent or Cys-Gly-Gly; Y is absent
79 or Cys; and Z is OH or NH₂; and

80 (b) detecting whether immunospecific binding has occurred between
81 the polypeptide and an antibody component of the body fluid in which an immune
82 complex is formed and in which the detection of the immune complex indicates the
83 presence of antibodies to HIV in the body fluid.

1 12. (Twice amended) A method for determining the presence of
2 antibodies to HIV-1 in a body fluid, comprising:

3 (a) contacting, under conditions which permit immunospecific binding
4 to form a reaction mixture, the body fluid with a composition containing at least one
5 polypeptide comprising at least one of the following polypeptide sequences:

6
7 (II) BRU124EX (SEQ ID NO: 2)

8 W-X-Leu-Gln-Lys-Gln-Ile-Thr-Lys-Ile-Gln-Asn-Phe-Arg-
9 Val-Tyr-Tyr-Arg-Asp-Ser-Arg-Asp-Pro-Leu-Trp-Lys-Gly-
10 Pro-Ala-Lys-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z

11
12 (III) BRU124FX1 (SEQ ID NO: 3)

13 W-X-Lys-Ile-Gln-Asn-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-
14 Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-
15 Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-Gln-Asp-Asn-Ser-Asp-
16 Ile-Lys-Y-Z

17
18 (IV) BRU124F3X (SEQ ID NO: 4)

19 W-X-Lys-Ile-Gln-Asp-Phe-Arg-Val-Tyr-Tyr-Arg-Asp-Ser-
20 Arg-Asp-Pro-Leu-Trp-Lys-Gly-Pro-Ala-Lys-Leu-Leu-Trp-
21 Lys-Gly-Glu-Gly-Ala-Val-Val-Ile-Gln-Asp-Asn-Y-Z

22
23 wherein W is either a H of the amino terminal NH₂ group of the
24 polypeptide or an additional amino acid bonded to the amino terminal NH₂ group of the
25 polypeptide, the additional amino acid being selected to facilitate coupling of the

26 polypeptide to a carrier protein or to a support; X is absent or Cys-Gly-Gly; Y is absent
27 or Cys; and Z is OH or NH₂; and

28 (b) detecting whether immunospecific binding has occurred between
29 the polypeptide and an antibody component of the body fluid in which an immune
30 complex is formed and in which the detection of the immune complex indicates the
31 presence of antibodies to HIV in the body fluid.

1 13. (Amended) A method for determining the presence of antibodies to
2 HIV-2 in a body fluid, comprising:

3 (a) contacting, under conditions which permit immunospecific binding
4 to form a reaction mixture, the body fluid with a composition containing at least one
5 polypeptide comprising at least six amino acids which come within at least one of the
6 following polypeptide sequences and including epitopes within such sequence:

7
8
9 (V) ROD 124E1 (SEQ ID NO: 5)

10
11 W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-
12 Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-
13 Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-Ala-
14 Y-Z
15

16 (VI) ROD 124EX (SEQ ID NO: 6)

17 W-X-Leu-Gln-Ala-Lys-Asn-Ser-Lys-Leu-Lys-
18 Asp-Phe-Arg-Val-Tyr-Phe-Arg-Glu-Gly-Arg-
19 Asp-Gln-Leu-Trp-Lys-Gly-Pro-Gly-Glu-Leu-
20 Leu-Trp-Lys-Gly-Glu-Gly-Ala-Y-Z
21

22 (VII) ROD 124C2X (SEQ ID NO: 7)

23
24 W-X-Lys-Leu-Lys-Asp-Phe-Arg-
25 Val-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-
26 Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-
27 Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-
28 Thr-Asp-Ile-Lys-Y-Z

29

30

(VIII) ROD 124C1X (SEQ ID NO: 8)

31

W-X-Tyr-Phe-Arg-Glu-Gly-Arg-Asp-Gln-Leu-

32

Trp-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-

33

Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-

34

Thr-Asp-Ile-Lys-Y-Z

35

36

(IX) ROD 123C3X (SEQ ID NO: 9)

37

X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-

38

Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-

39

Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-

40

Ala-Val-Leu-Val-Lys-Val-Gly-Thr-Asp-Ile-Lys-Y-

41

Z

42

43

(X) POL2A1 (SEQ ID NO: 10)

44

W-X-Lys-Gly-Pro-Gly-Glu-Leu-Leu-Trp-Lys-

45

Gly-Glu-Gly-Ala-Val-Leu-Val-Lys-Val-Gly-

46

Thr-Asp-Ile-Lys-Ile-Ile-Pro-Arg-Arg-Lys-

47

Ala-Lys-Ile-Ile-Y-Z

48

49

(XI) ROD124C5X (SEQ ID NO: 11)

50

W-X-Lys-Leu-Lys-Asp-Phe-Arg-Val-Tyr-Phe-

51

Arg-Glu-Gly-Arg-Asp-Gln-Leu-Trp-Lys-Gly-

52

Pro-Gly-Glu-Leu-Leu-Trp-Lys-Gly-Glu-Gly-

53

Ala-Val-Leu-Val-Lys-Val-Gly-Y-Z

54

55

56

wherein W is either a H of the amino terminal NH₂ group of the

57

polypeptide or an additional amino acid bonded to the amino terminal NH₂ group of the

58

polypeptide, the additional amino acid being selected to facilitate coupling of the

59

polypeptide to a carrier protein or to a support; X is absent or Cys-Gly-Gly; Y is absent

60

or Cys; and Z is OH or NH₂; and

*02
contd.*